Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 25, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for May 19, 2008 Subscribe to this News Feed      
 

FDA Discusses News Reports That Agency has Withheld Information on Chinese Drug Manufacturers of Heparin from Congress on Eye on FDA Podcast

In a new Eye on FDA podcast, blogger Mark Senak interviews FDA spokespeople regarding recent reports of information about Chinese drug manufacturers of heparin being withheld from Congress.

Washington, D.C. (PRWEB) May 19, 2008 - In a podcast posted to Eye on FDA by Mark Senak, Senior Vice President at Fleishman-Hillard in Washington, D.C., the Food and Drug Administration discussed reports that the agency has been withholding information from Congress regarding specific Chinese companies that manufacture heparin due to the existence of confidentiality agreements.

In February 2008, the FDA announced that Baxter International had temporarily stopped manufacturing multiple dose vials of heparin, a blood-thinning drug, due to reports of serious adverse events resulting in death. Since that time, reportedly 81 people have died and contamination has been discovered in eleven nations and products of multiple manufacturers.

The FDA has been conducting an investigation of the drug, and Congress has been holding hearings over the FDA's investigation and has delved into questions about how the heparin came to cause the adverse events.

On May 12, reports surfaced when The Wall Street Journal ran an article under the headline that stated "FDA Withholds List of Chinese Manufacturers From Probe" that suggests the FDA has been withholding information about Chinese manufacturers who develop components of heparin due to confidentiality agreements. On May 16, Mark Senak sat down with FDA spokespeople from FDA's CDER to get their take on these reports and will publish the conversation in a podcast to be posted on Eye on FDA on May 19, 2008.

Mark Senak's 'Eye on FDA'
'Eye on FDA' has a diverse 'readership', including national media, government officials, patient groups, law firms, stock analysts and pharmaceutical companies themselves.

# # #

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/U3VtbS1TcXVhLUluc2UtVGhpci1DcmFzLVplcm8=


Trackbacks/Comments Received

Zolpidem. from Cheap zolpidem. on Jun 23, 2008   Preview Open
Cheap zolpidem. Zolpidem overnight. Zolpidem and sleepwalking. Cheap zolpidem persriptions. Zolpidem eszopiclone indications. Zolpidem overdose.

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/U3VtbS1TcXVhLUluc2UtVGhpci1DcmFzLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Mark Senak
202-828-9703
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright